aTYR PHARMA INC - 8-K Filing

aTyr Pharma reports Q3 2026 results with $50.3 million in cash and announces FDA alignment on efzofitimod Phase 3 study protocol. (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)

SEC EDGAR · November 5, 2026, 21:06 UTC

Tickers: $ATYR

Read the full article at SEC EDGAR

Part of the story IDEAYA Biosciences, Inc. - 8-K Filing (42 articles)

More Regulatory news

Neonode Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 14:18 UTC
Beyond Air, Inc. - 10-Q Filing SEC EDGAR · November 12, 2026, 14:17 UTC
Carter Bankshares, Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 14:12 UTC
Marvell Technology, Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 14:11 UTC
VISHAY INTERTECHNOLOGY INC - 8-K Filing SEC EDGAR · November 12, 2026, 14:11 UTC
LATTICE SEMICONDUCTOR CORP - 4 Filing SEC EDGAR · November 12, 2026, 14:10 UTC
CENTRUS ENERGY CORP - 8-K Filing SEC EDGAR · November 12, 2026, 14:09 UTC
SAGA COMMUNICATIONS INC - 8-K Filing SEC EDGAR · November 12, 2026, 14:05 UTC
NextBoat Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 14:05 UTC
CIVISTA BANCSHARES, INC. - 8-K Filing SEC EDGAR · November 12, 2026, 14:05 UTC